TIRBANIBULIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H29N3O3
Molecular Weight	431.5277
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1ccc(cc1)CN=C(Cc2ccc(cn2)-c3ccc(cc3)OCCN4CCOCC4)O

InChI

InChIKey=HUNGUWOZPQBXGX-UHFFFAOYSA-N

InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)

HIDE SMILES / InChI

Molecular Formula	C26H29N3O3
Molecular Weight	431.5277
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737 | https://www.ncbi.nlm.nih.gov/pubmed/27737538

KX-01 is a dual inhibitor of Src kinase and tubulin polymerization. KX01 promotes the induction of p53, G2/M arrest of proliferating cell populations and subsequent apoptosis via the stimulation of Caspase-3 and PARP cleavage. The drug was developed by Kinex Pharmaceuticals and reached phase II of clinical trials for the treatment of Castration-Resistant Prostate Cancer and Actinic Keratosis. KX-01 demonstrated good in vitro pofile against different cancer cell lines with IC50 in nanomolar range.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase SRC 17 Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737 \| https://www.ncbi.nlm.nih.gov/pubmed/27737538	Inhibitor 7728
tubulin complex assembly 2 Target ID: GO:0007021 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737 \| https://www.ncbi.nlm.nih.gov/pubmed/27737538	Inhibitor 7728

Conditions

Condition	Modality	Targets	Highest Phase	Product
Castrate-resistant prostate cancer 19 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737	Primary		Phase II 1101	Unknown Approved Use Unknown
Actinic keratosis 10 Sources: https://clinicaltrials.gov/ct2/show/NCT02838628	Primary		Phase II 1101	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.	2011 Apr 15	21459579
Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities.	2011 Oct	21852023
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.	2012 Apr	21509526
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.	2013 Aug	23361621

Patents

Sample Use Guides

In Vivo Use Guide

Patients recieve 40 mg of oral KX-01 twice-daily. Ointment form should be applied once daily.

Route of Administration: Other

In Vitro Use Guide

PC3-LN4 human prostate cancer cells were treated with 10(-4)-10(4) nM of KX-01 for 72 hours and GI50 value was determined to be 40 nM.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:29:40 UTC 2021` Edited by `admin` on `Fri Jun 25 21:29:40 UTC 2021`
Record UNII	4V9848RS5G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIRBANIBULIN

Official Name

English

KX2391

Code

English

KX-2-391

Code

English

KLISYRI

Brand Name

English

2-PYRIDINEACETAMIDE, 5-(4-(2-(4-MORPHOLINYL)ETHOXY)PHENYL)-N-(PHENYLMETHYL)-

Systematic Name

English

N-BENZYL-2-(5-(4-(2-MORPHOLIN-4-YLETHOXY)PHENYL)PYRIDIN-2-YL)ACETAMIDE

Systematic Name

English

KX01

Code

English

TIRBANIBULIN [INN]

Common Name

English

TIRBANIBULIN [WHO-DD]

Common Name

English

KX-01

Code

English

TIRBANIBULIN [USAN]

Common Name

English

KX-2391

Code

English

KX2-391

Code

English

Code System Code Type Description

FDA UNII

4V9848RS5G